Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2618381 | 0.90 | PTGS2 (0.48) | BACE1ATRPTGS2PTGS1KMT2A | |
| SCHEMBL2618378 | 0.87 | PTGS2 (0.49) | ATRPTGS2PTGS1 | |
| SCHEMBL2602441 | 0.86 | PTGS2 (0.43) | NR1H2NR1H3PTGS2PTGS1 | |
| SCHEMBL2618382 | 0.85 | ATR (0.43) | BACE1ATRPTGS2PTGS1KMT2A | |
| SCHEMBL2618371 | 0.85 | ATR (0.43) | BACE1ATRPTGS2PTGS1KMT2A | |
| SCHEMBL2618380 | 0.85 | ATR (0.43) | BACE1ATRPTGS2PTGS1KMT2A | |
| SCHEMBL2618373 | 0.85 | PTGS2 (0.42) | NR1H2NR1H3BACE1ATRPTGS2 | |
| SCHEMBL2602393 | 0.84 | PTGS2 (0.57) | NR1H2NR1H3ATRPTGS2 | |
| SCHEMBL3439922 | 0.80 | ATR (0.47) | NR1H2NR1H3ATRPTGS2 | |
| SCHEMBL2618385 | 0.79 | ATR (0.38) | ATRPTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334302-B2 | Synthesis and anti-proliferative effect of substituted imidazo[4,5-b]pyridine compounds | SPELMAN COLLEGE (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120095037-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | SPELMAN COLLEGE (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095037-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | MKI67, CCNI, TYMP | NR1H2 4428/4885NR1H3 4416/4885BACE1 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.